If you liked this article you might like

Biomarin Newly Approved Drug for Rare, Childhood Disease Will Cost $700K Per Year
I'm Big on Housing Entering Quarter No. 2
Sarepta Opens Up About Duchenne Drug Launch, Allays Investors' Worst Fears
Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference